Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | MC3R | P41968 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27404283 | 0.80 | CCR1 (0.34) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL23089477 | 0.71 | KDM2B (0.33) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL30324540 | 0.71 | KDM2B (0.33) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL28897496 | 0.69 | DPP4 (0.41) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL30206029 | 0.69 | IKBKB (0.33) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL7040284 | 0.68 | ADORA2A (0.40) | GDAPIK3CDPOLBADORA3CNR1 | |
| SCHEMBL29175540 | 0.68 | L3MBTL1 (0.32) | HRH4HRH3 | |
| SCHEMBL30799631 | 0.68 | L3MBTL1 (0.32) | HRH4HRH3 | |
| SCHEMBL26640416 | 0.67 | DGAT1 (0.41) | HRH4HRH3 | |
| SCHEMBL24393386 | 0.65 | ADORA2A (0.41) | GDAPIK3CDPOLBADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | HRH4 2984/4885HRH3 3593/4885GDA 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.